Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Immunology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Lymphoma Clinical Trials

A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (421) clinical trials

Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies

This is a single arm pilot study for patients using / T cell-depleted PSCT in with alternative donor sources with hematologic malignancies receiving alternative donor (unrelated or partially matched related) mobilized peripheral stem cells (PSCs) using the CliniMACS system for T cell depletion plus CD19+ B cell depletion to determine ...

Phase

MSC and HSC Coinfusion in Mismatched Minitransplants

The present project aims at evaluating the capacity of MSC to improve one-year overall survival of patients transplanted with HLA-mismatched PBSC from related or unrelated donors after non-myeloablative conditioning. Co-infusion of MSC has been shown to facilitate engraftment of hematopoietic stem cell (HSC) in an immunodeficient mouse model. In addition, ...

Phase

Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy

The study aim is to evaluate the toxicity and activity of a therapeutic approach to high doses with support of peripheral blood stem cells (PBSC) in patients aged 65 and 75 years, chemosensitive relapsed or refractory to therapy first line in terms of event free survival (EFS) and treatment related ...

Phase

Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

PRIMARY OBJECTIVES: I. To estimate the complete response (CR) rate with ibrutinib at the standard dose of 560 mg daily in combination with nivolumab 3 mg/kg intravenously (IV) every 3 weeks up to 16 infusions in patients with relapsed or refractory classical Hodgkin lymphoma (cHL). SECONDARY OBJECTIVES: I. To determine ...

Phase

Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma

30 elderly patients age 60-85 with primary CNS DLBCL who will achieve response CR or PR will enter the study protocol maintenance phase. Induction treatment will include Rituximab and high dose methotrexate protocol (containing at least methotrexate and one more chemotherapy agent). Patients with MRI documented response CR or PR ...

Phase

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

Study Rationale Crizotinib is a selective ATP-competitive small-molecule inhibitor of the c-Met/HGFR and ALK receptor tyrosine kinases and their oncogenic variants (eg. c-Met/HGFR mutations or NPM-ALK fusion protein). Consistent with this mechanism of action, Crizotinib inhibited phosphorylation of c-Met/HGFR and NPM-ALK and their kinase target dependent functions in tumour cells ...

Phase

Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma

The aim of this study is to evaluate the efficacy of doxycycline in relapsed Cutaneous T-cell Lymphomas (CTCL). The primary objective is to determine the overall response rate of doxycycline monotherapy in patients with relapsed CTCL.

Phase

D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia

This study aims at exploring the activity of a frontline approach based on dasatinib plus steroids administration as induction treatment, followed by the infusion of Blinatumomab, in adult Ph+ ALL.

Phase

TGR1202 in Relapsed and Refractory Follicular Lymphoma

This is an open label, phase II study of TGR-1202 in patients with relapsed or refractory (R/R) Grade 1, 2, or 3A follicular lymphoma (FL). FL is the most common subtype of indolent lymphoma. The prognosis of FL depends on the histologic grade, stage, treatment and age of the patient. ...

Phase

Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)

The purpose of this trial is to determine Disease stabilization/response rate after six 21-day cycles of ibrutinib Remission status after six, twelve and 20 21-day cycles of ibrutinib

Phase